RxDoctor Payments Data

Nicole Waltrip, MD

Obstetrics & Gynecology · Wexford, PANPI 1356395677

Payments from drug & device makers

$820in general payments, 2019–2025

Across 21 payments — averaging $39.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$275
  • Mayne Pharma Commercial LLC$124
  • Hologic Sales And Service, LLC$108
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$62
  • Tosoh Bioscience, Inc.$47
  • Merck$38
  • plus $166 from 8 others

What the payments were for

  • Food & beverage$49861%
  • Education$27534%
  • Gifts$476%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$820 in reported general payments places this provider in the 65th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

See all obstetrics & gynecology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$19,658
Medicare patients
126
Services billed
359

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PremarinEstrogens, Conjugated48$20,066
MyrbetriqMirabegron15$14,195
Estradiol52$3,566
Estradiol (Once Weekly)Estradiol27$2,737
Clobetasol Propionate96$2,246
Estradiol (Twice Weekly)Estradiol16$2,197
ProgesteroneProgesterone, Micronized23$820
Ibandronate Sodium14$427
Alendronate Sodium47$316
ValacyclovirValacyclovir Hcl14$268
Fluconazole11$35

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerPremarin$12$20,06648 claims
Astellas Pharma US IncMyrbetriq$275$14,19515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,711 obstetrics & gynecology providers in Pennsylvania.

Other obstetrics & gynecology in Wexford

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →